Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Recommended
Cyclospora parasite illnesses have affected 28 NC counties, sickened more than 200 people
Recommended
Back to school guide: Buses, lunches, key dates
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Legend Biotech Corp ADR
(NQ:
LEGN
)
56.95
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Legend Biotech Corp ADR
< Previous
1
2
3
4
5
6
7
8
9
Next >
Short Volatility Alert: Legend Biotech Corporation
June 24, 2022
On Thursday, shares of Legend Biotech Corporation (NASDAQ: LEGN) experienced volatile short activity. After the activity, the stock price went up +6.97% to $51.10. The...
Via
Benzinga
Legend Biotech Shares Move Higher After Bullish BMO Pitch
June 17, 2022
Via
Benzinga
Short Volatility Alert: Legend Biotech Corporation
June 17, 2022
On Thursday, shares of Legend Biotech Corporation (NASDAQ: LEGN) experienced volatile short activity. After the activity, the stock price went down -1.38% to $42.96. The...
Via
Benzinga
How Newcomer Arcellx Is Looking To Rival Johnson & Johnson In Cancer
June 06, 2022
This biotech stock launched in February to work on CAR-T treatments.
Via
Investor's Business Daily
Longer-Term Data from CARTITUDE Program Continue to Show Deep and Durable Responses with Ciltacabtagene Autoleucel Across Lines of Therapy in Patients with Multiple Myeloma
June 04, 2022
From
Legend Biotech
Via
Business Wire
Legend Biotech Announces U.S. FDA Clearance of IND Application for Solid Tumor CAR-T, LB1908 for Relapsed or Refractory Gastric, Esophageal and Pancreatic Cancers
June 03, 2022
From
Legend Biotech
Via
Business Wire
Legend Biotech Reports First Quarter 2022 Financial Results and Recent Highlights
June 01, 2022
From
Legend Biotech
Via
Business Wire
Legend Biotech to Host Investors at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
May 31, 2022
From
Legend Biotech
Via
Business Wire
Week In Review: Fosun Acquires VerImmune Cancer Immunotherapy In $125 Million Deal
May 28, 2022
Fosun Pharma acquired China rights to a novel broad cancer immunotherapy candidate from VerImmune of Baltimore in an $125 million agreement. Fosun will pay VerImmune up to $125 million in upfront and...
Via
Talk Markets
The Daily Biotech Pulse: Setback For NRx Pharma's COVID Study, Fast Track Tag For Pfizer's NASH Combo Therapy, Reata's Ataxia Drug In FDA Review
May 26, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
CARVYKTI® (ciltacabtagene autoleucel) Granted Conditional Approval by the European Commission for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
May 26, 2022
From
Legend Biotech
Via
Business Wire
Legend Biotech to Highlight Continued Progress in the Treatment of Multiple Myeloma With Updated Data From BCMA CAR-T Studies at 2022 ASCO and EHA
May 18, 2022
From
Legend Biotech
Via
Business Wire
Legend Biotech Appoints Lori Macomber as Chief Financial Officer
May 09, 2022
From
Legend Biotech
Via
Business Wire
Legend Biotech Announces Participation in Upcoming Investor Conferences
May 06, 2022
From
Legend Biotech
Via
Business Wire
HFCAA News: 128 Chinese Stocks the SEC Could Delist
May 05, 2022
The SEC has released a massive list of Chinese stocks that could face delisting on Holding Foreign Companies Accountable Act news.
Via
InvestorPlace
Legend Biotech Announces Appointment of Global Head of Research and Early Development
April 01, 2022
From
Legend Biotech Corporation
Via
Business Wire
Most Chinese Biotech Stocks Can Continue US Listing After New Audit Framework
April 01, 2022
Via
Benzinga
EMA's CHMP Clears Janssen, Legend's Multiple Myeloma CAR-T Therapy
March 25, 2022
The European Medicines Agency's CHMP
Via
Benzinga
CARVYKTI® (ciltacabtagene autoleucel) Receives Positive CHMP Opinion for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
March 25, 2022
From
Legend Biotech
Via
Business Wire
Flanders Investment and Trade Names Legend Biotech Newcomer of the Year
March 23, 2022
From
Legend Biotech
Via
Business Wire
Legend Biotech Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights
March 18, 2022
From
Legend Biotech
Via
Business Wire
Analyst Ratings For Legend Biotech
March 15, 2022
Analysts have provided the following ratings for Legend Biotech (NASDAQ:LEGN) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 15, 2022
March 15, 2022
Upgrades For Turquoise Hill Resources Ltd (NYSE:TRQ), BMO Capital upgraded the previous rating of Underperform to Market Perform. Turquoise Hill Resources earned $0.78 in the...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
March 14, 2022
Gainers Erytech Pharma (NASDAQ:ERYP) stock rose 18.7% to $1.65 during Monday's pre-market session. The market value of their outstanding shares is at $51.1 million....
Via
Benzinga
The Week Ahead In Biotech (March 6-12): Quiet Week On Tap With Earnings Season Reaching It Final Leg
March 06, 2022
Biotech stocks reversed course in the week ending March 4, as the Ukrainian crisis weighed down on the broader market as well as the sector. The iShares Biotechnology ETF (...
Via
Benzinga
Week In Review: Adagene Forms $2.5 Billion, Four-Drug Partnership With Sanofi
March 05, 2022
Adagene will apply its technology to as many as four Sanofi candidates in a collaboration worth up to $2.5 billion. Huadong Medicine will acquire Asia rights for two Heidelberg Pharma ADC candidates in...
Via
Talk Markets
GenScript Losses Widen, But Investors Focus on Newly Approved Cancer Treatment
March 01, 2022
Key takeaways: GenScript Biotech said it lost up to $519 million last year, with its Legend Biotech unit accounting for nearly 70% of that Legend Biotech’s Cilta-cel CAR-T...
Via
Benzinga
The Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent Resolution
March 01, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Editas Gains On Resolution Of CRISPR Gene Editing Patent Case Editas Medicine...
Via
Benzinga
FDA Approves JNJ-Legend Biotech Partnered Blood Cancer Therapy
March 01, 2022
The FDA has approved Legend Biotech Corporation's (NASDAQ: LEGN) first product, Carvykti (ciltacabtagene autoleucel; cilta-cel), for relapsed or refractory...
Via
Benzinga
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
February 27, 2022
Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first two sessions of the...
Via
Talk Markets
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.